CVR number 28858523
Industry 869500

FYSIOVEJEN AUTORISEREDE FYSIOTERAPEUTER ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  7.1% 8.1% 6.3% 5.8% 7.1%  
Credit score (0-100)  34 29 37 39 34  
Credit rating  BBB BB BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Gross profit  1,865 2,101 2,215 2,419 2,398  
EBITDA  432 484 523 594 772  
EBIT  417 475 507 553 733  
Pre-tax profit (PTP)  412.9 468.5 467.4 448.3 621.1  
Net earnings  321.9 365.2 361.7 342.6 476.8  
Pre-tax profit without non-rec. items  413 469 467 448 621  
 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Tangible assets total  17.9 8.0 2,344 2,303 2,263  
Shareholders equity total  448 491 487 470 606  
Interest-bearing liabilities  19.9 0.0 1,903 1,797 1,787  
Balance sheet total (assets)  961 901 2,639 2,580 2,685  
Net Debt  -518 -543 1,900 1,792 1,729  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  1,865 2,101 2,215 2,419 2,398  
Gross profit growth  -8.2% 12.7% 5.4% 9.2% -0.9%  
Employees  4 4 5 4 4  
Employee growth %  0.0% 0.0% 25.0% -20.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  961 901 2,639 2,580 2,685  
Balance sheet change%  19.1% -6.2% 192.8% -2.2% 4.1%  
Added value  431.6 484.4 523.1 568.7 772.4  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -29 -20 2,320 -83 -79  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  22.4% 22.6% 22.9% 22.8% 30.6%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  47.2% 51.0% 28.6% 21.2% 27.8%  
ROI %  82.8% 92.0% 34.7% 23.7% 31.5%  
ROE %  68.9% 77.7% 73.9% 71.6% 88.6%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  46.6% 54.5% 18.5% 18.2% 22.6%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -119.9% -112.0% 363.2% 301.6% 223.8%  
Gearing %  4.4% 0.0% 390.7% 382.7% 294.7%  
Net interest  0 0 0 0 0  
Financing costs %  41.7% 61.3% 4.2% 5.6% 6.2%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  1.7 2.0 0.4 0.3 0.5  
Current Ratio  1.8 2.1 0.4 0.4 0.6  
Cash and cash equivalent  537.5 542.6 3.0 5.4 58.3  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  371.5 427.1 -338.2 -399.3 -286.3  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  108 121 105 142 193  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  108 121 105 149 193  
EBIT / employee  104 119 101 138 183  
Net earnings / employee  80 91 72 86 119